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Abstract
Background: Diabetes imposes a substantial burden globally in terms of premature mortality, morbidity, and health care
costs. Estimates of economic outcomes associated with diabetes are essential inputs to policy analyses aimed at prevention
and treatment of diabetes. Our objective was to estimate and compare event rates, hospital utilization, and costs associated
with major diabetes-related complications in high-, middle-, and low-income countries.
Methods and Findings: Incidence and history of diabetes-related complications, hospital admissions, and length of stay
were recorded in 11,140 patients with type 2 diabetes participating in the Action in Diabetes and Vascular Disease
(ADVANCE) study (mean age at entry 66 y). The probability of hospital utilization and number of days in hospital for major
events associated with coronary disease, cerebrovascular disease, congestive heart failure, peripheral vascular disease, and
nephropathy were estimated for three regions (Asia, Eastern Europe, and Established Market Economies) using multiple
regression analysis. The resulting estimates of days spent in hospital were multiplied by regional estimates of the costs per
hospital bed-day from the World Health Organization to compute annual acute and long-term costs associated with the
different types of complications. To assist, comparability, costs are reported in international dollars (Int$), which represent a
hypothetical currency that allows for the same quantities of goods or services to be purchased regardless of country,
standardized on purchasing power in the United States. A cost calculator accompanying this paper enables the estimation
of costs for individual countries and translation of these costs into local currency units. The probability of attending a
hospital following an event was highest for heart failure (93%–96% across regions) and lowest for nephropathy (15%–26%).
The average numbers of days in hospital given at least one admission were greatest for stroke (17–32 d across region) and
heart failure (16–31 d) and lowest for nephropathy (12–23 d). Considering regional differences, probabilities of
hospitalization were lowest in Asia and highest in Established Market Economies; on the other hand, lengths of stay
were highest in Asia and lowest in Established Market Economies. Overall estimated annual hospital costs for patients with
none of the specified events or event histories ranged from Int$76 in Asia to Int$296 in Established Market Economies. All
complications included in this analysis led to significant increases in hospital costs; coronary events, cerebrovascular events,
and heart failure were the most costly, at more than Int$1,800, Int$3,000, and Int$4,000 in Asia, Eastern Europe, and
Established Market Economies, respectively.
Conclusions: Major complications of diabetes significantly increase hospital use and costs across various settings and are
likely to impose a high economic burden on health care systems.
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The prevalence of diabetes worldwide was estimated to be 2.8%
in 2000 and projected to rise to 4.4% by 2030, with more than
three-quarters of people with diabetes living in developing
countries [1]. Diabetes imposes a considerable burden in terms
of premature mortality, morbidity, and health care costs. Life
expectancy for people with diabetes has been estimated to be up to
10 y shorter than for people without diabetes [2–4]. Likewise
diabetes imposes substantial demands on health care systems, as
medical expenditures for people with diabetes are up to three
times greater than for those without diabetes, largely because of
macrovascular complications [5–7].
Currently there is a paucity of information on the direct medical
costs associated with treating diabetes in low- and middle-income
countries [8]. For example, lacking microlevel data, a recent
estimate of the global health care costs of treating diabetes was
based on country-level information regarding total health care
spending, the prevalence of diabetes, and ratios of the costs of care
for people with and without diabetes [9]. Although such an
approach provides estimates of the overall resources devoted to the
treatment of diabetes, it provides no indication of how different
types of complications contribute to health care costs.
Health care resources devoted to people with diabetes may
differ across countries because of a wide variety of factors
including different rates of complications and the case fatality
associated with events, as well as patterns of treatment such as the
frequency and length of hospital episodes. Estimates of the
resource use associated with treating different types of events
associated with diabetes are essential inputs to projections of the
economic burden of diabetes. These inputs are also needed in
economic evaluations of interventions for prevention or treatment
of diabetes, in order to quantify costs that may be averted owing to
lower rates of complications.
The purpose of this study was to estimate acute and long-term
resource use associated with five major complications of diabetes,
on the basis of patient-level information from the Action in
Diabetes and Vascular Disease (ADVANCE) study [10], a
multinational clinical trial that included over 11,000 participants
from 20 countries. Focusing on three groups of countries defined
by geography and level of economic development, we examined
variation in rates of major complications and used regression
models to estimate the short-term and long-term hospital use
associated with these events. Combining these estimates with
estimated hospital bed-day costs from the World Health
Organization’s (WHO) CHOICE project [11], we estimated the
total annual hospital costs associated with major complications
among patients with diabetes in different regions.
Methods
Study Population
All patients included in this analysis were participants in the
ADVANCE (Action in Diabetes and Vascular Disease: Preterax
and Diamicron MR Controlled Evaluation) study. ADVANCE
was a randomised 262 factorial trial in 11,140 normotensive
patients with type 2 diabetes comparing (i) gliclazide MR-based
intensive glucose control regimen, or regular, guideline-based
glucose control therapy in patients with type 2 diabetes, and (ii)
routine blood pressure lowering based on a perindopril-indapa-
mide combination or matching placebo [12]. The gliclazide MR-
based intensive blood glucose control regimen aimed to reduce
haemoglobin A1C to 6.5% or lower (compared with haemoglobin
A1C targets of 7%–8% suggested by most regional guidelines)
[10]. As the focus of the current study was on variation in hospital
use associated with major complications, rather than on the
outcomes associated with particular therapies, the analysis was
based on all participants in the study. ADVANCE is registered
with ClinicalTrials.gov, number NCT00145925.
Patients were eligible for the trial if they had been diagnosed
with type 2 diabetes mellitus at the age of 30 y or older, were aged
55 y or older at entry to the study, and had a history of major
macrovascular disease or at least one other risk factor for
macrovascular disease. The eligibility criteria were intentionally
designed to enroll a broad cross-section of high-risk patients [12].
In this study countries are grouped into three regions. The
countries (with numbers of randomized patients in parentheses) in
each region are: Asia (4,136) comprising China (3,293), India
(471), Malaysia (236), and the Philippines (136); Eastern Europe
(2,142) comprising the Czech Republic (209), Estonia (155),
Hungary (434), Lithuania (118), Poland (604), Russia (164), and
Slovakia (458); and Established Market Economies (4,862)
comprising Australia (978), Canada (436), France (196), Germany
(327), Ireland (442), Italy (21), The Netherlands (507), New
Zealand (630), and the United Kingdom (1,325). These regions are
compatible with the World Bank’s geographic regions, as Asia
comprises countries from the World Bank’s South Asia and East
Asia and Pacific regions and Eastern Europe comprises countries
from the World Bank’s Europe and Central Asia region.
Identification of Complications and Hospitalizations
Five prespecified endpoints from the study were used in the
analysis: (i) major coronary events; (ii) major cerebrovascular
events; (iii) heart failure; (iv) peripheral vascular events; and (v) new
or worsening nephropathy. Outcomes were coded according to
the 10th Revision of the International Classification of Diseases.
Information on hospitalization (including admission for less than
one day) was collected from all patients during the trial at their
regular clinic visits or at the time of death, if relevant [10].
Statistical Methods
The cumulative incidence of events was plotted by region, and
standard log-rank methods without adjustment for covariates were
used to test for significant differences across regions. Annual
estimates of the probability of admission to the hospital and the
total number of days spent in hospital were calculated using
regression models for longitudinal (panel) data [13–15]. For this
analysis, hospital use was separated into two periods: (i) use during
the year in which the complication occurs, and (ii) use in all
subsequent years. Indicator variables were defined for each of the
five types of complications, and distinguishing these two different
periods. Other variables in the models included current age, sex,
and region. We included an indicator variable for having more
than one type of event in the same year to enable multiple
complications to have a combined impact on hospital use or length
of stay that differed from the sum of the individual effects. We also
included indicator variables for mortality to capture different
patterns of resource use near the time of death. Separate mortality
variables were defined for each region and for three categories of
events based on preliminary analyses indicating similar effects for
the specific complications comprising each category: (i) coronary
events or heart failure; (ii) cerebrovascular events; and (iii) all other
deaths. Finally, we included indicator variables for study years (i.e.,
years since randomization) to allow for time-varying effects that
were not captured in the other model covariates.
Two separate regression equations were estimated to model
health care use. In both models, each individual contributes
multiple observations, and the statistical models account for
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was used to model the annual probability of having at least one
hospitalization, including random effects at the patient level.
Second, a negative binomial regression was used to model counts
of the total number of days spent in hospital within a year, given at
least one hospital admission. The negative binomial regression was
estimated using a generalized estimating equation approach with a
log link [16]. As a preliminary analysis provided strong evidence of
overdispersion in these data (p,0.0001 on a likelihood ratio test),
the negative binomial model was used in preference to Poisson
estimation. Similar two-part modeling approaches are commonly
used in estimating cost and utilization functions for many types of
health care [17], as these approaches enable explicit modeling of
the decision to seek care, separate from the intensity of utilization.
Methods for Estimating Total Expected Hospital Use and
Associated Costs
The expected annual number of days spent in hospital, given a
particular event or event history, was computed by multiplying the
estimated probability of hospitalization (calculated using the
logistic regression equation) by the estimated annual number of
days for those hospitalized (calculated using the negative binomial
regression equation). The proportional contributions of each type
of complication and multiple complications during the follow-up
period were estimated and reported by region.
In order to compute estimated costs, we combined the regional
estimates of expected hospital use in this study with estimated
hospital bed-day costs made available by WHO’s CHOICE
project (www.who.int/choice). The methodology for estimating
these bed-day costs has been described in detail elsewhere [11]. In
brief, cross-country regression models were applied to a dataset
compiled from secondary literature and unpublished reports on
cost analyses in hospitals and health centres in 49 countries,
between 1973 and 2000, totaling 2,173 country-years of
observations. Cost data were adjusted for inflation using gross
domestic product (GDP) deflator series and adjusted for currency
differences using purchasing-power–parity exchange rates. Cost
functions were estimated using ordinary least squares regression,
relating the natural log of costs per hospital bed-day to the natural
log of GDP per capita, the natural log of the hospital occupancy
rate, and indicator variables for hospital level (primary, secondary,
or tertiary), hospital type (public or private), and the inclusion of
drug or food costs. For the present study we computed region-
specific bed-day costs by applying the published coefficients from
the WHO-CHOICE regression model [11] to estimates of 2008
GDP per capita from the World Bank (computed as regional
averages reflecting the distribution across countries in the study
population). We assumed a tertiary-level, public not-for-profit
hospital, and included food but not drug costs. As a sensitivity
analyses we also computed estimates for secondary-level hospitals.
Total costs were calculated as the product of the estimated
probability of hospitalization, the estimated number of hospital
days given admission, and the estimated hospital per diem cost. To
account for uncertainty in these estimates we recomputed the
results with 1,000 bootstrapped regression coefficient estimates for
each of the three components. All costs are presented in 2008
international dollars (Int$), which represent a hypothetical
currency that allows for the same quantities of goods or services
to be purchased regardless of country, standardized on purchasing
power in the US. While the main analyses in this paper report
estimates at the regional level, we also present examples of
calculations for selected countries. Costs for all countries involved
in the ADVANCE study are readily available using a cost
calculator provided as a supplement to this paper (Dataset S1).
The cost calculator reports costs in international dollars as well as
in local currency units, and also enables calculation of costs under
various alternative assumptions, for example about hospital level.
All statistical analyses were undertaken using STATA 10.1 and
the cost calculator is implemented as an Excel spreadsheet.
Results
Some regional differences were observed in the baseline
characteristics of the population (Table 1). Compared with
participants from Established Market Economies participants in
the other regions were younger and more likely to be female.
Blood pressure was substantially higher among Eastern European
patients, who had a mean blood pressure at entry of 150/85 mm
Hg. Body mass index was on average significantly lower among
Asian patients.
A total of 10,955 hospitalizations were recorded during the
study follow-up (median duration of follow-up was 5.0 y). The
average numbers (standard deviation [SD]) of hospitalizations per
participant during the trial by region were: Asia 0.7 (1.2); Eastern
Europe 0.9 (1.6); Established Market Economies 1.3 (1.9).
Significant differences across regions were observed in the
cumulative incidence of the five types of complications and all-
cause mortality (Figure 1). Compared with patients from
Established Market Economies those in Eastern Europe had
significantly higher incidence of cerebrovascular events (Figure 1B),
heart failure (Figure 1C), and peripheral vascular disease
(Figure 1D). In Asia the incidence of coronary events (Figure 1A)
and peripheral vascular disease was significantly lower, whereas
the incidence of stroke and nephropathy (Figure 1E) was
significantly higher.
The two-part regression results are reported in Table 2. These
results may be used to predict hospital utilization among patients
of a particular age and living in a particular region, in a year in
which the patient either experiences a specific first complication or
has a history of past complications. The regional predictions of
complication-specific hospital use are reported in Table 3 for
nonfatal complications. The first section reports probabilities of
hospitalization following each type of complication. Overall,
probabilities of hospitalization were highest for heart failure
(93%–96% across regions); probabilities of hospitalization for
coronary and cerebrovascular events were slightly lower. The
lowest probabilities occurred for nephropathy (15%–26% across
regions). Comparable probabilities for fatal events are available in
Dataset S1. For coronary events and heart failure, fatal events
were associated with lower probabilities of admission in all regions,
presumably owing to acute fatality occurring before reaching
hospital. Probabilities of admission were similar between fatal and
nonfatal stroke events, while other types of complications were
associated with greater probabilities of hospital use preceding fatal
events. Across regions, probabilities of having at least one hospital
admission were highest in Established Market Economies and
lowest in Asia.
The second section in Table 3 shows average numbers of
inpatient bed-days per year given at least one hospitalization in
that year. Numbers of days spent in hospital were greatest for
stroke (17–32 across regions) and heart failure (16–31) and smallest
for nephropathy (12–23). Again the estimated models also enable
calculation of comparable figures for fatal complications (Dataset
S1). Fatal coronary events and heart failure had shorter predicted
lengths of stay in all regions; differences between fatal and nonfatal
stroke varied by region; and length of stay increased in all regions
for all other events and for those without complications. The
overall comparison of length of stay across regions has the opposite
Hospital Use for Diabetes Complications
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length of stay in the absence of any of the specified complications
in this study at nearly 19 d for Asia compared to 12 d in Eastern
Europe and 10 d in Established Market Economies.
The final section in Table 3 reports estimated regional costs
associated with the different types of complications, on the basis of
the estimated numbers of total bed-days from ADVANCE,
combined with WHO-CHOICE estimates of hospital per diem
costs. Overall estimated annual hospital costs for patients with
none of the specified events or event histories ranged from Int$76
in Asia to Int$296 in Established Market Economies. All
complications included in this analysis led to significant increases
in hospital costs. Coronary events, cerebrovascular events, and
heart failure were the most costly, at more than Int$1,800,
Int$3,000, and Int$4,000 in Asia, Eastern Europe, and Established
Market Economies, respectively. Patients with a history of
complications continued to have higher hospital use and costs in
subsequent years relative to those without any history of
complications. In a sensitivity analysis assuming that costs were
incurred in secondary-level rather than tertiary-level hospitals, we
found that costs were approximately 30% lower than those
reported in the main analysis.
Although Table 3 presents regional estimates it is also possible
to estimate country-specific costs by applying WHO-CHOICE
hospital per diem estimates derived from national GDP per capita.
For example, using this approach the estimated annual costs
associated with nonfatal coronary events were Int$1,871 (95%
confidence interval 1,260–2,857) for China, Int$2,655 (1,734–
3,975) for Russia, and Int$3,947 (2,535–5,842) for the UK. The
provided cost calculator (Dataset S1) enables estimation of hospital
use and costs for any country in the ADVANCE study, assuming
any specified hospital level, and expressed in either international
dollars or local currency units.
Figure 2 shows the contributions from each type of specified
complication to overall hospital use by region during the 5-y
follow-up of the study. The complications identified in this study
contributed the highest proportion of hospital use in Eastern
Europe (approximately two-thirds), primarily due to the higher
incidence of macrovascular events such as heart failure. In Asia
these five complications contributed 60% to overall hospital use,
with about half of the use associated with cerebrovascular events.
Discussion
In this study we have reported results from analyses of a large
patient-level dataset collected in 20 countries (including seven
countries in Eastern Europe and four in Asia) to obtain empirical
estimates of the hospital use and indicative costs associated with a
set of major complications that occur commonly in people with
diabetes. There were significant differences in both the incidence
of these complications and in patterns of hospital use across
regions. Overall, patients in Asia and Eastern Europe had higher
incidence of some events (e.g., stroke) than patients in Established
Market Economies, lower rates of hospitalization, and longer
lengths of stay. Specific complications varied markedly in their
contributions to hospital use across regions. For example in Asia
around 30% of days spent in hospital by people with diabetes
could be attributed to stroke, whereas heart failure was more
important in Eastern Europe. In both of these regions, major
complications contributed a greater proportion of the hospital use
recorded during the study than in Established Market Economies.
In addition to estimating hospital use directly from the
ADVANCE data, we have also reported on estimated costs
associated with this use, applying the hospital per diem costing
methodology developed by WHO’s CHOICE project. These cost
estimates are intended to quantify hospital resource use associated
with these events and not simply the cost of the admission for the
event. Costs are reported in this paper using international dollars, as
this approach facilitates comparability across regions by capturing
differences in purchasing power for both traded and nontraded
goods [18]. The models presented here can also be used to calculate
Table 1. Characteristics of study participants at baseline.
Baseline Participant Characteristics Region
Asia Eastern Europe Established Market Economies
n 4,136 2,142 4,862
Age (y), mean (SD) 65.1 (5.7) 65.9 (7.0) 67.7 (6.4)
Male, n (%) 2,207 (53) 949 (44) 3,249 (67)
Duration of diabetes at diagnosis (y), mean (SD) 8.5 (6.3) 8.3 (6.4) 7.6 (6.4)
History of macrovascular disease
Myocardial infarction, n (%) 264 (6) 336 (16) 734 (15)
Stroke, n (%) 576 (14) 172 (8) 275 (6)
Major risk factors
Serum haemoglobin A1c concentration (%), mean (SD) 7.8 (1.8) 7.6 (1.7) 7.3 (1.2)
Systolic blood pressure (mm Hg), mean (SD) 141 (22) 150 (22) 146 (21)
Diastolic blood pressure (mm Hg), mean (SD) 79 (11) 85 (11) 81 (10)
Serum total cholesterol (mmol/L), mean (SD) 5.3 (1.2) 5.7 (1.3) 4.9 (1.0)
Serum LDL cholesterol (mmol/L), mean (SD) 3.2 (1.0) 3.5 (1.1) 2.9 (1.0)
Serum HDL cholesterol (mmol/L), mean (SD) 1.3 (0.4) 1.3 (0. 3) 1.2 (0.3)
Body mass index (kg/m2), mean (SD) 25.3 (3.4) 30.6 (5.0) 30.0 (5.3)
Current smokers, n (%) 576 (14) 377 (18) 729 (15)
HDL, high-density lipoprotein; LDL, low-density lipoprotein; SD, standard deviation.
doi:10.1371/journal.pmed.1000236.t001
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involved in the ADVANCE study, and for various combinations of
complications based on the reported regression equations. To
facilitate use of these models we have developed a simple
spreadsheet-based tool that can be used to calculate hospital costs
for all countries involved in ADVANCE (Dataset S1). It is also
possible to refine costing estimates using supplementary costing
information when available, such as hospital per diem costs by
specialty in a specific country. The modular approach presented in
this paper—with separate components for estimating probabilities
of admission, length of stay, and bed-day costs—allows for flexibility
in substituting estimates derived from other available sources for
any of the three components.
An important motivation behind this analysis has been to
develop a set of hospital cost estimates for major complications in
patients with diabetes in Asian and Eastern European countries.
To put our estimates into some perspective, recent estimates
reported by WHO indicate an average annual per capita health
expenditure of Int$216 for China and Int$698 for Russia [19].
Our results indicate that the annual hospital costs for people with
diabetes experiencing major macrovascular complications such as
coronary or cerebrovascular events are between four and ten times
these average per capita expenditures. When interpreting these
results it is important to note that this study has focused on hospital
inpatient use and costs. Reports from developed countries have
consistently observed that costs of inpatient care represent around
Figure 1. Cumulative incidence of major complications and all-cause mortality in the ADVANCE study, by region. (A–E) Major
complications. (F) All-cause mortality.
doi:10.1371/journal.pmed.1000236.g001
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hospitalization.
Variablesa
Part 1: Annual Probability of
Hospitalization—Logistic Regression
Part 2: Annual Number of Hospital
Bed-Days—Negative Binomial Regression
Coeff SE Coeff SE
Constant 22.208 0.048 2.303 0.035
Male 0.038
* 0.037 20.057 0.027
Current Age: 68.5
b 0.032 0.003 0.017 0.002
Region
Asia 20.701 0.043 0.660 0.032
Eastern Europe 20.452 0.050 0.230 0.037
Event in this year
Major coronary
c 5.189 0.233 0.358 0.061
Major cerebrovascular
d 4.749 0.175 0.545 0.057
Heart failure
e 5.441 0.244 0.505 0.061
Peripheral vascular
f 1.536 0.101 0.422 0.066
Nephropathy
g 1.162 0.123 0.191 0.080
History of event
MC
c 0.392 0.050 0.064
* 0.035
Major cerebrovascular
d 0.259 0.057 0.120 0.040
HF
e 0.622 0.080 0.304 0.053
Peripheral vascular
f 0.372 0.104 0.337 0.071
Nephropathy
g 0.667 0.126 0.027
* 0.084
Multiple events
h 21.724 0.315 0.065
* 0.100
Death with a MC or HF event
i
EME 23.187 0.288 20.055
* 0.111
Asia 23.053 0.328 21.057 0.142
Eastern Europe 23.202 0.339 20.671 0.135
Death with a stroke event
j
EME 0.827
* 1.090 0.193
* 0.201
Asia 20.496
* 0.531 20.499 0.209
Eastern Europe 20.239
* 0.735 0.274
* 0.227
Any other death
k
EME 2.753 0.163 0.737 0.073
Asia 3.183 0.211 0.436 0.100
Eastern Europe 2.625 0.241 0.167
* 0.125
Pseudo-R-squared 0.12
Numbers of observations 58,715 8,004
aFive indicator variables representing panel-specific (time) effects have been omitted for the sake of brevity.
bCurrent age is centered, by deducting the mean age (across all person-years of observation) of 68.5 y.
cNonfatal myocardial infarction or death from coronary heart disease.
dNonfatal stroke or death from cerebrovascular disease.
eAll heart failure events leading to death, requiring hospital admission or resulting in an increase in NYHA class.
fAll peripheral vascular events including death due to peripheral vascular disease, amputation of at least one digit, requirement for a peripheral revascularization, or
chronic ulceration of a lower limb thought due to arterial insufficiency.
gAny of the following: the development of macroalbuminuria; a doubling of serum creatinine to a level of at least 200 mmol/l; the requirement for renal replacement
therapy (dialysis or transplantation); or death from renal disease.
hIndicates more than one type of predefined event occurred in the same year;
iDeath occurred within the same year as a MC or HF event.
jDeath occurred within the same year as a stroke event.
kDeath occurred in any year without a MC, HF, or stroke event.
*Not significant at p.0.05.
Coeff, coefficient; EME, Established Market Economies; HF, heart failure; MC, major coronary; SE, standard error.
doi:10.1371/journal.pmed.1000236.t002
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hospitalization, by region.
Complication Status Asia Eastern Europe Established Market Economies
Mean
95% Confidence
Intervals Mean
95% Confidence
Intervals Mean
95% Confidence
Intervals
Probability of hospitalization
All patients 0.080 (0.074–0.086) 0.108 (0.100–0.118) 0.149 (0.141–0.158)
No complications
a 0.053 (0.048–0.058) 0.067 (0.060–0.074) 0.101 (0.094–0.108)
Event in this year
Major coronary 0.909 (0.880–0.938) 0.927 (0.903–0.951) 0.953 (0.936–0.968)
Major cerebrovascular 0.865 (0.821–0.905) 0.892 (0.857–0.925) 0.928 (0.901–0.950)
Heart failure 0.928 (0.885–0.963) 0.943 (0.909–0.971) 0.963 (0.940–0.982)
Peripheral vascular 0.205 (0.170–0.240) 0.249 (0.209–0.288) 0.342 (0.295–0.387)
Nephropathy 0.151 (0.118–0.187) 0.185 (0.145–0.230) 0.264 (0.214–0.317)
History of event
Major coronary 0.076 (0.067–0.086) 0.095 (0.083–0.110) 0.142 (0.128–0.158)
Major cerebrovascular 0.067 (0.059–0.076) 0.085 (0.073–0.096) 0.127 (0.113–0.142)
Heart failure 0.094 (0.079–0.111) 0.117 (0.099–0.139) 0.173 (0.147–0.201)
Peripheral vascular 0.075 (0.059–0.091) 0.094 (0.075–0.115) 0.140 (0.114–0.166)
Nephropathy 0.098 (0.076–0.124) 0.122 (0.094–0.155) 0.179 (0.141–0.221)
Length of stay (d)
All patients 19.5 (18.0–21.3) 13.4 (12.3–14.5) 10.7 (9.9–11.7)
No complications
a 18.8 (17.2–20.6) 12.2 (11.2–13.3) 9.7 (8.8–10.6)
Event in this year
Major coronary 26.9 (23.2–31.0) 17.5 (15.3–20.2) 13.9 (12.2–16.0)
Major cerebrovascular 32.4 (28.1–37.7) 21.1 (18.0–25.0) 16.8 (14.3–19.6)
Heart failure 31.2 (26.9–35.9) 20.3 (17.5–23.3) 16.1 (13.9–18.5)
Peripheral vascular 28.7 (23.4–35.0) 18.7 (15.5–22.8) 14.8 (12.2–17.8)
Nephropathy 22.8 (18.1–28.0) 14.8 (11.9–18.2) 11.8 (9.3–14.5)
History of event
Major coronary 20.0 (17.6–22.6) 13.0 (11.4–14.6) 10.4 (9.1–11.5)
Major cerebrovascular 21.2 (19.0–23.9) 13.8 (12.3–15.7) 11.0 (9.7–12.4)
Heart failure 25.5 (21.6–30.1) 16.6 (14.2–19.5) 13.2 (11.1–15.3)
Peripheral vascular 26.3 (21.0–32.4) 17.1 (13.9–21.2) 13.6 (10.9–16.7)
Nephropathy 19.3 (14.9–24.4) 12.6 (9.6–15.8) 10.0 (7.6–12.7)
Estimated cost (2008 Int$)
All patients 121 (80–181) 276 (180–409) 483 (312–711)
No complications
a 76 (51–114) 156 (100–232) 296 (191–435)
Event in this year
Major coronary 1,887 (1,270–2,881) 3,103 (2,004–4,633) 4,002 (2,569–5,923)
Major cerebrovascular 2,166 (1,474–3,273) 3,598 (2,351–5,312) 4,703 (3,046–6,914)
Heart failure 2,232 (1,480–3,375) 3,655 (2,344–5,311) 4,687 (2,971–6,719)
Peripheral vascular 454 (283–727) 888 (543–1,341) 1,533 (920–2,292)
Nephropathy 265 (160–428) 525 (311–824) 937 (548–1,460)
History of event
Major coronary 118 (77–184) 238 (150–368) 445 (276–667)
Major cerebrovascular 110 (72–169) 223 (141–341) 420 (262–633)
Heart failure 185 (117–292) 372 (228–572) 687 (417–1,048)
Peripheral vascular 152 (93–251) 307 (185–493) 575 (341–911)
Nephropathy 146 (89–237) 293 (172–471) 541 (315–847)
aNo complications signifies none of the five complications listed.
doi:10.1371/journal.pmed.1000236.t003
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24], and this pattern of resource use is also reflected in more recent
studies in developing countries [25,26]. However, complications of
diabetes can demand resources from other elements in the health
system as well (e.g., increased use of outpatient services), and the
fraction of all costs relating to hospital inpatient stays may vary
across regions. Quantifying resource use and associated costs for
the other health system elements should be a focus for future work,
as the rising prevalence of diabetes globally is likely to require
considerable additional health care resources to treat these and
other major complications of diabetes.
Another important use of the information provided in this study
is to provide essential inputs to economic evaluations. Cost-
effectiveness analyses of interventions to manage diabetes
conducted in developed countries often show that a significant
proportion of the implementation costs are offset by savings in
future treatment costs because of lower rates of complications
[27,28]. There is a need to undertake comparable studies of cost-
effectiveness of alternative interventions for the treatment and
prevention of diabetes in different regions (particularly in low- and
middle-income countries). Our results can inform such analyses by
providing estimates of the hospital resource use for countries in
Asia and Eastern Europe. In this regard it will be useful to
undertake a reexamination of the limited existing economic
evaluations of diabetes that have been conducted in these regions,
which have not accounted for regional differences in the incidence
of complications [29], or have been confined to intermediate
outcomes such as costs per case of diabetes prevented [30].
How do these results compare with previous studies reporting
resource use and costs for major complications of diabetes? In
regard to developed countries, the average lengths of stay for
diabetic patients having macrovascular events in the UK are similar
to previous estimates [31]. Our estimated annual costs for
cerebrovascular events and heart failure also appear to be
comparable with these previous estimates, but prior estimates of
the cost of coronary heart disease events are around 50% higher
than those reported here [31]. These cost differences for coronary
heart disease are mostly likely due to higher costs associated with the
specialty cardiology care of around £400 per day in the earlier
study [31], compared with the WHO-CHOICE estimate of Int$302
used in this study. The reporting of the probability of hospitalization
and average annual length of stay for each complication facilitates
the calculation of additional estimates where other information on
hospital bed-day costs is available. In terms of other comparisons,
the hospital costs reported here for several macrovascular events
appear to be of similar magnitude to a recent Chinese hospital-
based cross-sectional study [26], but other studies have reported a
wide variation in these costs [29]. For many other countries such as
Russia we can find no published estimates available.
This study involves patients recruited by 215 centres in the
ADVANCE study who were seen regularly in clinics over an
average period of 5 y as part of a wider clinical trial. Although
having prospectively collected information on the complications of
a large group of patients is a key strength, it should also be noted
that elements of the trial design and entry criteria may limit the
applicability of the results to a broader patient population. Caution
is therefore warranted in generalizing from the trial to all diabetic
patients. Because the ADVANCE study intervention involved use
of pharmacological therapies, we expect that absolute rates of
complications in the trial may differ from those in general practice;
on the other hand, because the trial protocol did not specify how
patients with major complications would be treated in hospital, we
expect that the frequency and intensity of hospital utilization in the
trial will be more robust and generalizable to routine practice.
While it would be useful to undertake prospective costing studies
outside of clinical trials, the infrastructure costs associated with
recruitment and follow-up of large cohorts of people with diabetes
are likely to be important barriers to this form of data collection in
many countries. Given persistent gaps in the evidence base on the
economics of diabetes outcomes in low- and middle-income
countries, this study provides critical information on patterns of
hospital resource use and costs in settings where there have been
no previous longitudinal studies.
To summarise, we expect that the estimates reported here will
help inform the evaluation of therapies aimed at preventing
diabetes-related complications, as they provide explicit quantifi-
cation of the potential to avert future health care costs through
successful secondary prevention. These results are required for
decision makers who need to anticipate future health care costs for
people with diabetes, or who wish to examine the cost-effectiveness
of interventions aimed at reducing the rates of complications.
Health care providers, policy makers, and health service
researchers require timely information on the expected health
and economic consequences of diabetes. Understanding the
relative burden associated with different complications will provide
critical evidence for health care decisions characterized by
Figure 2. Contributions of specific complications to total hospital use during the ADVANCE study, by region. ‘‘No complications’’
signifies none of the five complications listed. EME, Established Market Economies.
doi:10.1371/journal.pmed.1000236.g002
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settings constrained by severely limited resources.
Supporting Information
Dataset S1 Cost calculator for major complications of diabetes.
Found at: doi:10.1371/journal.pmed.1000236.s001 (9.69 MB
XLS)
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Background. Worldwide, nearly 250 million people have
diabetes, and this number is increasing rapidly. Diabetes is
characterized by dangerous amounts of sugar (glucose) in
the blood. Blood sugar levels are normally controlled by
insulin, a hormone produced by the pancreas. Blood sugar
control fails in people with diabetes because they make no
insulin (type 1 diabetes) or, more commonly, because the fat
and muscle cells that usually respond to insulin by removing
excess sugar from the blood have become insulin insensitive
(type 2 diabetes). Type 2 diabetes can be prevented and
controlled by eating a healthy diet and exercising regularly. It
can also be treated with drugs that help the pancreas make
more insulin or that increase insulin sensitivity. Major long-
term complications of diabetes include kidney failure and an
increased risk of cardiovascular problems such as heart
attacks, heart failure, stroke, and problems with the blood
vessels in the arms and legs. Because of these complications,
the life expectancy of people with diabetes is about ten
years shorter than that of people without diabetes.
Why Was This Study Done? Diabetes imposes
considerable demands on health care systems but little is
known about the direct medical costs associated with
treating this chronic disease in low- and middle-income
countries where more than three-quarters of affected people
live. In particular, although estimates have been made of the
overall resources devoted to the treatment of diabetes, very
little is known about how the different long-term
complications of diabetes contribute to health care costs in
different countries. Public-health experts and governments
need this information to help them design effective and
sustainable policies for the prevention and treatment of
diabetes. In this study, the researchers estimate the resource
use associated with diabetes-related complications in three
economic regions using information collected in the Action
in Diabetes and Vascular Disease (ADVANCE) study. This
multinational clinical trial is investigating how drugs that
control blood pressure and blood sugar levels affect the
long-term complications of diabetes.
What Did the Researchers Do and Find? The researchers
recorded diabetes-related complications, hospital admissions
for these complications, and length of hospital stays in
11,140 patients with severe diabetes from 20 countries who
participated in the ADVANCE study. They used ‘‘multiple
regression analysis’’ to estimate the number of days spent in
hospital for diabetes-related complications in Asia, Eastern
Europe, and the Established Market Economies (Canada,
Australia, New Zealand, and several Western European
countries). Finally, they calculated the economic costs of
each complication using regional estimates of the costs per
bed-day from the World Health Organization’s CHOICE
project (CHOosing Interventions that are Cost Effective).
Nearly everyone in the study who developed heart failure
attended a hospital, but only 15%–26% of people attended a
hospital for kidney problems. The chances of hospitalization
for any complication were lowest in Asia and highest in the
Established Market Economies; conversely, lengths of stay
were longest in Asia and shortest in the Established Market
Economies. Finally, the estimated annual hospital costs for
patients who had a coronary event, stroke, or heart failure
were more than Int$1,800, Int$3,000, and Int$4,000 in Asia,
Eastern Europe, and the Established Market Economies,
respectively (the international dollar, Int$, is a hypothetical
currency that has the same purchasing power in all
countries), compared to Int$76, Int$156, and Int$296 for
patients who experienced none of these events.
What Do These Findings Mean? Because the ADVANCE
trial had strict entry criteria, the findings of this study may
not be generalizable to the broader population of people
with diabetes. Nevertheless, given the lack of information
about the costs associated with diabetes-related
complications in low- and middle-income countries, these
findings provide important new information about the
patterns of hospital resource use and costs in these
countries. Specifically, these findings show that the major
complications of diabetes greatly increase hospital use and
costs in all three economic regions considered and impose a
high economic burden on health care systems that is likely
to increase as the diabetes epidemic develops. Importantly,
these findings should help policy makers anticipate the
future health care costs associated with diabetes and should
help them evaluate which therapies aimed at preventing
diabetes-related complications will reduce these costs most
effectively.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000236.
N The International Diabetes Federation provides informa-
tion about all aspects of diabetes
N The US National Diabetes Information Clearinghouse
provides detailed information about diabetes for patients,
health care professionals, and the general public (in
English and Spanish)
N The UK National Health Service also provides information
for patients and caregivers about type 2 diabetes (in
several languages)
N Information about the ADVANCE study is available
N The World Health Organization’s CHOICE Web site provides
information about the analysis of the cost effectiveness of
health care interventions
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